Yong, Kol JiaLi, AilingOu, Wen-BinHong, Clarice Kit YeeZhao, WenxiuWang, FeiTatetsu, HiroYan, BenedictQi, LihuaFletcher, JonathanYang, HenrySoo, RossTenen, DanielChai, Li2017-04-062016Yong, K. J., A. Li, W. Ou, C. K. Y. Hong, W. Zhao, F. Wang, H. Tatetsu, et al. 2016. “Targeting SALL4 by entinostat in lung cancer.” Oncotarget 7 (46): 75425-75440. doi:10.18632/oncotarget.12251. http://dx.doi.org/10.18632/oncotarget.12251.http://nrs.harvard.edu/urn-3:HUL.InstRepos:32072105The overall survival of lung cancer patients remains dismal despite the availability of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein report that SALL4 was aberrantly expressed in a subset of lung cancer patients with poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment led to impaired lung cancer cell growth. Expression profiling of SALL4-knockdown cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. Connectivity Map analysis revealed the HDAC inhibitor entinostat as a potential drug in treating SALL4-expressing cancers, and this was confirmed in 17 lung cancer cell lines. In summary, we report for the first time that entinostat can target SALL4-positive lung cancer. This lays the foundation for future clinical studies evaluating the therapeutic efficacy of entinostat in SALL4-positive lung cancer patients.en-USentinostatHDAC inhibitorlung cancerSALL4Journal Article2017-04-0610.18632/oncotarget.12251